132 / 144
132
PERGUNTAS & RESPOSTAS
EMD
- Edema Macular Diabético
Referências
1. Aroca PR, Salvat M, Fernandez J, Mendez I. Risk factors for diffuse and focal macular
edema. J Diabetes Compl. 2004;18:211-215.
2. Early Treatment Diabetic Retinopathy Study Research Group. Photocoagulation for dia-
betic macular edema. Early Treatment Diabetic Retinopathy Study report number1. Arch
Ophthalmol. 1985;103(12): 1796-1806.
3. Jyothi S, Sivaprasad S. Five-year visual outcome following laser photocoagulation of dia-
betic macular oedema. Eye (Lond). 2011 Jul;25(7):851-8; quiz 859. PMID: 21587271.
4. Wells JA, Glassman AR, Ayala AR et al. The Diabetic Retinopathy Clinical Research
Network A`ibercept, Bevacizumab or Bevacizumab for Diabetic Macular Edema N
Engl J Med. 2015 March 26;372(13):1193-1203.
5. Wells JA, Glassman AR, Ayala AR et al. Diabetic Retinopathy Clinical Research
Network, A`ibercept, bevacizumab, or ranibizumab for diabetic macular edema: two-
-year results from a comparative effectiveness randomized clinical trial. Ophthalmolo-
gy. 2016;123:1351-1359.
6. Augustin AJ, Kuppermenn B D, Lanzetta P, Loewenstein A et al. for the Ozurdex MEAD
Study Group Dexamethasone intravitreal implant in previously treated patients with
diabetic macular edema: subgroup analysis of the MEAD study. BMC Ophthalmol.
2015;15:150.
7. Cunha-Vaz J, Ashton P, Iezzi R, et al. for the FAME Study Group. Sustained delivery
`uocinolone acetonide vitreous implants: long-term bene%t in patients with chronic
diabetic macular edema. Ophthalmology. 2014;121(10):1892-1903.
8. Campochiaro A, Brown DM, Pearson A, et al. Sustained delivery `uocinolone acetoni-
de vitreous inserts provide bene%t for at least 3 years in patients with diabetic macular
edema. Ophthalmology. 2012;119:2125-32.
9. Gale R, Carneiro A, Zaeytijd J, Figueira J et al. The importance of Ocular, Systemic and
Psychosocial Factors in the Management of the Diabetic Macular Oedema Patient with
Anti-Vascular Endothelial Growth Factor Therapy, Expert Recommendations and Litera-
ture Review. European Ophthalmic Review. 2016;10(2):117-124.
10. Elman MJ, Aiello LP, Beck RW, et al. for the Diabetic Retinopathy Clinical Resear-
ch Network. Randomized trial evaluating ranibizumab plus prompt or deferred laser
or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology.
2010;117(6):1064-1077.
11. Elman MJ, Bressler NM, Qin H, et al. for the Diabetic Retinopathy Clinical Research
Network. Expanded 2-year follow- up of ranibizumab plus prompt or deferred laser
or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology.
2011;118(4):609-614.
12. Elman MJ, Qin H, Aiello LP, et al. for the Diabetic Retinopathy Clinical Research
Network. Intravitreal ranibizumab for diabetic macular edema with prompt versus
deferred laser treatment: three-year randomized trial results. Ophthalmology. 2012
Nov;119(11):2312-2318.
13. Nguyen QD, Brown DM, Marcus DM, et al. RISE and RIDE Research Group, Ranibizu-
mab for diabetic macular edema: results from 2 phase III randomized trials: RISE and
RIDE. Ophthalmology. 2012:119:789-801.
14. Brown DM, Nguyen QD, Marcus DM, et al. Long-term outcomes of ranibizumab thera-
py for diabetic macular edema: the 36 month results from two phase III trials: RISE and